AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17760727 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment with amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 20 mg b.i.d. for 14 days in patients with positive (13)C-UBT.
Number of subjects: 78
Study 17760727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no H. pylori eradication treatment).
Number of subjects: 78
Study 15172264 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraaortic balloon pump (IABP) therapy
Number of subjects: 133
Study 15172264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 133
Study 11827603 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated-care program
Number of subjects: 24
Study 11827603 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided system
Number of subjects: 24
Study 9725756 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg oral)
Number of subjects: 0
Study 9725756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9065553 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (2 g/kg intravenous immunoglobulin)
Number of subjects: 19
Study 9065553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9065553 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 19
Study 1775594 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐ala‐Peptide‐T‐amide (Peptide T) intravenous administration at doses ranging from 0.1 to 3.2 mg/kg/day for 12 weeks
Number of subjects: 14
Study 1775594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Peptide T at 25 mg/day for 8 weeks after a 4-week off-drug period
Number of subjects: 14
Study 1775594 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no drug administration)
Number of subjects: 14
Study 7046652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV, 500 mg weekly
Number of subjects: 30
Study 7046652 — intervention group
Group type: COMPARATOR
Intervention: Saline solution, 10 ml
Number of subjects: 30
Study 29862630 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 100
Study 29862630 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study 28423038 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional bias training
Number of subjects: 137
Study 28423038 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 137
Study 26511489 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucoraphanin (GFN) supplement providing Sulforaphane (SFN)
Number of subjects: 54
Study 26511489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25092356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (MLE)
Number of subjects: 563
Study 25092356 — intervention group
Group type: COMPARATOR
Intervention: Lateral episiotomy (LE)
Number of subjects: 563
Study 25092356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MLE and LE
Number of subjects: 563
Study 22876876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin/5-FU
Number of subjects: 201
Study 22876876 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin/capecitabine
Number of subjects: 201
Study 22876876 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU
Number of subjects: 201
Study 22876876 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine based regimens
Number of subjects: 201
Study 19615806 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional-writing condition
Number of subjects: 148
Study 19615806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact-writing condition
Number of subjects: 148
Study 19615806 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 148
Study 19615806 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participants group (n=66)
Number of subjects: 148
Study 17239882 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage autotransfusion
Number of subjects: 112
Study 17239882 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 112
Study 15128968 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-about-violence program
Number of subjects: 161
Study 15128968 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat stigma program
Number of subjects: 161
Study 15128968 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 12638739 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Hz EA
Number of subjects: 13
Study 12638739 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Hz TENS
Number of subjects: 13
Study 12638739 — intervention group
Group type: EXPERIMENTAL
Intervention: 100Hz TENS
Number of subjects: 13
Study 9170595 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sucking
Number of subjects: 18
Study 9170595 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sucking
Number of subjects: 18
Study 1438647 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (1 mg/kg)
Number of subjects: 12
Study 1438647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4026972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion to reach blood alcohol concentration of 1 mg/ml in 1 hr
Number of subjects: 6
Study 4026972 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion (control)
Number of subjects: 6
Study 31997539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (via the Optimizer System) plus standard of care (SoC)
Number of subjects: 3
Study 31997539 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 3
Study 29308539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11083
Study 29308539 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11083
Study 29308539 — intervention group
Group type: EXPERIMENTAL
Intervention: Every SD increase in HGI
Number of subjects: 11083
Study 29308539 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 11083
Study 26651863 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Behavior Group (EBG)
Number of subjects: 63
Study 26651863 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Only Group (EG)
Number of subjects: 63
Study 26651863 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study 24423203 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth prescribed edgewise bracket systems
Number of subjects: 33
Study 24423203 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon 3MX bracket system
Number of subjects: 33
Study 22042946 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4724
Study 22042946 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4724
Study 20529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinic agents
Number of subjects: 0
Study 18807574 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants (20 implants)
Number of subjects: 40
Study 18807574 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of dental implants (20 implants)
Number of subjects: 40
Study 16076515 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO partograph training and implementation by midwives
Number of subjects: 20
Study 16076515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no partograph training)
Number of subjects: 20
Study 11799005 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-portal technique
Number of subjects: 16
Study 11799005 — intervention group
Group type: COMPARATOR
Intervention: Three-portal technique
Number of subjects: 16
Study 10716066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17-beta-estradiol (300 microg)
Number of subjects: 36
Study 10716066 — intervention group
Group type: COMPARATOR
Intervention: Reservoir patch (50 microg/day of 17-beta-estradiol)
Number of subjects: 36
Study 10716066 — intervention group
Group type: COMPARATOR
Intervention: Tablet (2 mg micronised 17-beta-estradiol)
Number of subjects: 36
Study 8538478 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest 50 twice weekly for 12 weeks
Number of subjects: 214
Study 8538478 — intervention group
Group type: COMPARATOR
Intervention: Premarin 0.625 mg daily for 12 weeks
Number of subjects: 214
Study 8538478 — intervention group
Group type: EXPERIMENTAL
Intervention: Menorest and Premarin
Number of subjects: 214
Study 1985041 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment (psychotherapy, relaxation, and standard medical treatment)
Number of subjects: 102
Study 1985041 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 102
Study 6650773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine carotid artery heterografts (BCAH)
Number of subjects: 0
Study 6650773 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene grafts (PTFE)
Number of subjects: 0
Study 30511258 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 19932
Study 30511258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19932
Study 30451560 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group intervention (8 weekly sessions of 1.5 hours each)
Number of subjects: 40
Study 26817916 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 209
Study 26817916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-MSH6 expression
Number of subjects: 209
Study 26817916 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MSH6 expression
Number of subjects: 209
Study 26817916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor differentiation, postoperative chemotherapy, and pre-MSH6 expression
Number of subjects: 209
Study 26817916 — intervention group
Group type: EXPERIMENTAL
Intervention: ypN category and perineural invasion
Number of subjects: 209
Study 24534207 — intervention group
Group type: EXPERIMENTAL
Intervention: αTMS treatment group
Number of subjects: 46
Study 24534207 — intervention group
Group type: COMPARATOR
Intervention: Sham control group
Number of subjects: 46
Study 21392832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Stem Cells (BMSC) intracoronary infusion
Number of subjects: 45
Study 21392832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 20178593 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 17567869 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg 3 times daily for 4 weeks
Number of subjects: 18
Study 17567869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16368577 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg vitamin C twice daily until 34 weeks' gestation
Number of subjects: 0
Study 16368577 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo twice daily until 34 weeks' gestation
Number of subjects: 0
Study 12501129 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP increased from 400 mg/day to 600 mg/day
Number of subjects: 25
Study 12501129 — intervention group
Group type: COMPARATOR
Intervention: Standard NVP dosing (400 mg/day)
Number of subjects: 25
Study 11477814 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Huanshuai recipe (YSHSR)
Number of subjects: 46
Study 11477814 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet and controlling blood pressure
Number of subjects: 46
Study 11477814 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 46
Study 7814752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% citric acid
Number of subjects: 10
Study 7814752 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1‐adrenolytic agent
Number of subjects: 10
Study 7814752 — intervention group
Group type: COMPARATOR
Intervention: Control (no adrenolytic agents)
Number of subjects: 10
Study 7814752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1‐adrenolytic agent
Number of subjects: 10
Study 2597600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 50
Study 2597600 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 50
Study 5579197 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal mode
Number of subjects: 34
Study 5579197 — intervention group
Group type: COMPARATOR
Intervention: Board mode
Number of subjects: 34
Study 5579197 — intervention group
Group type: COMPARATOR
Intervention: Computer mode
Number of subjects: 34
Study 31894993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacotherapy
Number of subjects: 156
Study 31894993 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined symptom trajectory
Number of subjects: 156
Study 30926125 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 2249
Study 30926125 — intervention group
Group type: COMPARATOR
Intervention: Unexplained Infertility (UI)
Number of subjects: 2249
Study 28087049 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Chest Drainage (DCD) system
Number of subjects: 37
Study 28087049 — intervention group
Group type: COMPARATOR
Intervention: Classic drainage system
Number of subjects: 37
Study 26432909 — intervention group
Group type: EXPERIMENTAL
Intervention: H2N2 LAIV
Number of subjects: 0
Study 26432909 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N2 LAIV
Number of subjects: 0
Study 26432909 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N3 LAIV
Number of subjects: 0
Study 26432909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22736121 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 597
Study 22736121 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 597
Study 20399553 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (250U)
Number of subjects: 72
Study 20399553 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 or 50mg/day)
Number of subjects: 72
Study 18560253 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 64
Study 18560253 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 64
Study 15777891 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron therapy of 100 mg of elemental iron
Number of subjects: 220
Study 15777891 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of iron sorbitol intramuscularly, repeated at an interval of 4‐6 weeks
Number of subjects: 220
Study 12464749 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington disease patients
Number of subjects: 0
Study 12464749 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 10521094 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos selected based on well-shaped first polar bodies
Number of subjects: 158
Study 10521094 — intervention group
Group type: COMPARATOR
Intervention: Control group with embryos selected based on degree of embryo fragmentation
Number of subjects: 158
Study 8629458 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol and 150 micrograms desogestrel
Number of subjects: 416
Study 8629458 — intervention group
Group type: COMPARATOR
Intervention: 30 micrograms ethinylestradiol and 75 micrograms gestodene
Number of subjects: 416
Study 2140547 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 120
Study 2140547 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice daily
Number of subjects: 120
Study 6895145 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescope technique
Number of subjects: 121
Study 6895145 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Number of subjects: 121
Study 6895145 — intervention group
Group type: COMPARATOR
Intervention: Central approach
Number of subjects: 121
Study 31939912 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking combined with exercises to improve balance and strength (W + EX)
Number of subjects: 94
Study 31939912 — intervention group
Group type: COMPARATOR
Intervention: Walking-only (WALK)
Number of subjects: 94
Study 30056363 — intervention group
Group type: EXPERIMENTAL
Intervention: First Episode Psychosis (FEP) patients
Number of subjects: 208
Study 30056363 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP-NA patients
Number of subjects: 208
Study 30056363 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP patients
Number of subjects: 208
Study 30056363 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 208
Study 27918586 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient (MM) supplements (15 micronutrients with similar amounts of IFA)
Number of subjects: 5011
Study 27918586 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-Folic Acid (IFA) supplements (60 mg Fe and 2800 μg FA)
Number of subjects: 5011
Study 27918586 — intervention group
Group type: COMPARATOR
Intervention: Control group (2800 μg FA)
Number of subjects: 5011
Study 24862430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 58
Study 24862430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22192331 — intervention group
Group type: EXPERIMENTAL
Intervention: Der p-SIT + pharmacotherapy
Number of subjects: 46
Study 22192331 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy only
Number of subjects: 46
Study 20557388 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based training
Number of subjects: 30
Study 20557388 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive self-guided learning
Number of subjects: 30
Study 20557388 — intervention group
Group type: COMPARATOR
Intervention: Yoked control group
Number of subjects: 30
Study 20557388 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended students
Number of subjects: 30
Study 18540926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 36
Study 18540926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.05%
Number of subjects: 36
Study 18540926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.025%
Number of subjects: 36
Study 15940378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 29
Study 15940378 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated children with severe OI)
Number of subjects: 29
Study 12880463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil diameter of 2 mm (miotic)
Number of subjects: 10
Study 12880463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil diameters of 4 mm, 6 mm, 8 mm
Number of subjects: 10
Study 12880463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil area
Number of subjects: 10
Study 10692737 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1570
Study 10692737 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1570
Study 7502276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac infusion
Number of subjects: 29
Study 7502276 — intervention group
Group type: COMPARATOR
Intervention: Non-ketorolac group
Number of subjects: 29
Study 7502276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 1778354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment and/or increase of physical activity or training
Number of subjects: 222
Study 1778354 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervened subjects with impaired glucose tolerance and normal control subjects)
Number of subjects: 222
Study 6954092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized aerosol salbutamol (0.1-2.4 mg)
Number of subjects: 17
Study 6954092 — intervention group
Group type: COMPARATOR
Intervention: Powder aerosol salbutamol (0.2-4.8 mg)
Number of subjects: 17
Study 6954092 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized aerosol beclomethasone dipropionate (200, 500, 1000 micrograms q.i.d.)
Number of subjects: 17
Study 6954092 — intervention group
Group type: COMPARATOR
Intervention: Powder aerosol beclomethasone dipropionate (200, 500, 1000 micrograms q.i.d.)
Number of subjects: 17
Study 31972609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed outreach leveraging social psychology and behavioral economics principles (intervention arm)
Number of subjects: 2000
Study 31972609 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (text-based letter describing and offering FIT and colonoscopy)
Number of subjects: 2000
Study 30782127 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 224
Study 30782127 — intervention group
Group type: COMPARATOR
Intervention: Regular activities
Number of subjects: 224
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: Th17 cells in acute leukemia patients (CD3+ CD4+ IL‐17+)
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ CD25+ Foxp3+ cells in acute leukemia patients
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL‐17 levels in acute leukemia patients
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TGF‐β levels in acute leukemia patients
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: RORγT mRNA levels in acute leukemia patients
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: Foxp3 mRNA levels in acute leukemia patients
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: Th17 cells and CD4+ CD25+ Foxp3+ cells after 6 months of chemotherapy
Number of subjects: 40
Study 28650331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL‐17 and TGF‐β levels after 6 months of chemotherapy
Number of subjects: 40
Study 25738177 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm implants
Number of subjects: 60
Study 25738177 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.5 mm implants
Number of subjects: 60